Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnosticsBASKING RIDGE, N.J. and ...